Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 14/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611375 | 0.81 | CYP17A1 (0.43) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL11961681 | 0.78 | CYP17A1 (0.41) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL11961971 | 0.78 | HSP90AB1 (0.34) | CYP3A4PNPALDH1A1HRH3 | |
| SCHEMBL13604221 | 0.78 | HRH3 (0.42) | PNPALDH1A1HRH3 | |
| SCHEMBL13604219 | 0.78 | LTB4R (0.49) | PNPMEN1ALDH1A1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL5042672 | 0.77 | HRH3 (0.41) | PNPALDH1A1HRH3 | |
| SCHEMBL7371292 | 0.75 | LOXL2 (0.44) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL4439445 | 0.74 | ALDH1A1 (0.51) | LMNAKDM4EALDH1A1CYP2D6HPGD | |
| SCHEMBL1136768 | 0.72 | CYP17A1 (0.51) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL14521955 | 0.70 | MAPK14 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708701-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7625921-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625921-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7605264-B2 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605264-B2 | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1708699-A4 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- K .B ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1708699-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- K .B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182110-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| WO-2005072729-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182110-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | NR3C1, NFRKB, NCOR1 | CYP17A1 181/4885CYP11B1 86/4885CYP11B2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.